Publication: Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX™ detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8
Authors
Dian, Darius ; Lenhard, Miriam ; Mayr, Doris ; Heublein, Sabine ; Karsten, Uwe ; Goletz, Steffen ; Kuhn, Christina ; Wiest, Irmi ; Friese, Klaus ; Weissenbacher, Tobias ; Jeschke, Udo
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
y. PankoMab-GEX™ is a novel humanized and
glycooptimized antibody, which recognizes a novel
specific tumour epitope of MUC1 (TA-MUC1). The aim
of this study was to evaluate PankoMab-GEX™ binding
to a variety of ovarian cancer specimens (n=156) and to
normal ovarian tissue. In addition, PankoMab-GEX™
staining was compared to that of the well-known antiMUC1
antibodies HMFG-1 and 115D8. PankoMabGEX™
showed positive reactivity in serous (100% of
cases, mean IRS 8.23), endometrioid (95% of cases,
mean IRS 6.40), mucinous (58% of cases, mean IRS
4.17), and clear cell (92% of cases, mean IRS 7.58)
carcinomas. In contrast to HMFG-1, healthy ovarian
tissue was not recognized by PankoMab-GEX™.
Staining with antibody 115D8 was increased with
staging. Cytoplasmic PankoMab-GEX™ staining
increased with tumour grade, but no correlation was
found with staging. Univariate Kaplan-Meier analysis
revealed a tendency of reduced survival of patients with
high expression of TA-MUC1. The findings are
encouraging with respect to a potential use of
PankoMab-GEX™ as a new therapeutic antibody for the
treatment of ovarian cancer patients.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.